AZ has nearly 50% of workforce in emerging markets as it keeps ‘sharp eye’ on costs
This article was originally published in Scrip
Executive Summary
AstraZeneca has implemented a significant reallocation of resources from established to emerging markets, adding 6,400 ‘permanent’ personnel last year in the latter as it gears to expand and build capabilities in some of the most promising markets including China and Russia.